Comparative evaluation of subgingivally delivered 1% alendronate versus 1.2% atorvastatin gel in treatment of chronic periodontitis: a randomized placebo-controlled clinical trial.
OBJECTIVE
Alendronate (ALN) and atorvastatin (ATV) are known to inhibit osteoclastic bone resorption and were proposed to have osteostimulative properties. The aim of the study was to evaluate and compare the efficacy of 1% ALN and 1.2% ATV gel as a local drug-delivery system in adjunct to scaling and root planning (SRP) for the treatment of intrabony defects in chronic periodontitis patients.


METHODS
A total of 90 intrabony defects were treated with either 1% ALN, 1.2% ATV, or placebo gel. Clinical parameters (plaque index, modified sulcus bleeding index, probing depth (PD), and clinical attachment level (CAL)) were recorded at baseline, 3, 6, and 9 months. Intrabony defect depth (IBD) and defect depth reduction (DDR%) was calculated on standardized radiographs at 6 and 9 months.


RESULTS
The mean PD reduction, CAL gain, and DDR% were greater in the ALN and ATV group than in the placebo group at 3, 6, and 9 months. Furthermore, a significantly greater DDR% was found in the ALN group at 6 and 9 months than in the ATV and placebo groups.


CONCLUSIONS
Local delivery of 1% ALN results in significantly greater improvement in PD, CAL, IBD depth, and DDR% as compared to 1.2% ATV gel.
Department of Periodontology, Government Dental College and Research Institute, Bangalore, Karnataka, India.
Avani R
AR
Pradeep
Department of Periodontology, Government Dental College and Research Institute, Bangalore, Karnataka, India.
Dharmendra
D
Kanoriya
Department of Periodontology, Government Dental College and Research Institute, Bangalore, Karnataka, India.
Sandeep
S
Singhal
Department of Periodontology, Government Dental College and Research Institute, Bangalore, Karnataka, India.
Vibhuti
V
Garg
Department of Periodontology, Pacific Dental College, Jaipur, India.
Balaji
B
Manohar
Department of Periodontology, The Oxford Dental College and Hospital, Bangalore, Karnataka, India.
Anirban
A
Chatterjee
D000328:Adult; D019386:Alendronate / Q000008:administration & dosage*; D000069059:Atorvastatin / Q000008:administration & dosage*; D055113:Chronic Periodontitis / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged
D005782:Gels; D000069059:Atorvastatin; D019386:Alendronate
alendronate; atorvastatin; chronic periodontitis; osteoclast